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General pustular psoriasis (GPP) is a rare form of
psoriasis and is clinically characterized by wide-
spread eruptions of sterile pustules and bright
erythematous skin accompanied by periods of fever,
chills, rigors, neutrophilia, and elevated serum C-
reactive protein.1 Acrodermatitis of Hallopeau, pal-
moplantar psoriasis pustulosis, and annular pustular
psoriasis may be variations of this GPP.2 In 2011,
Marrakchi et al3 reported a subgroup of GPP patients
with a specific genetic defect: a deficiency of
interleukin-36 receptor antagonist (DITRA). We
report a case of juvenile DITRA successfully treated
with acitretin in combination with etanercept.
CASE REPORT
We present a case of a child that was referred to us
at the age of 2 months. She was the first child of 2
consanguineous Moroccan parents. No complica-
tions were reported during pregnancy or delivery
(gestational age at delivery was 41 weeks and
6 days). There was no family history of psoriasis.
The first week postpartum, multiple pustules ap-
peared in the perioral and diaper area. At the age of
7 weeks, an erythroderma developed with macera-
tions in the folds (Fig 1, A). Zinc level, complement-
5, and lymphocyte subsets were normal. Chest
radiograph was normal, and no hair or nailDepartment of Dermatology, Sophia Children’s Hospital,
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seborrheic dermatitis was made at that time, and she
was treated with topical steroids with a good
response.
In the following months, she had recurrent
episodes of erythroderma, fever, vomiting, failure
to thrive, leukocytosis, and elevated acute-phase
protein levels. At 6 months, she was admitted to
the hospital for diarrhea and imminent dehydration.
Palmoplantar confluent pustules were seen, suspect
for pediatric acral pustulosis or pustular psoriasis.
Topical steroids were sufficient to stabilize the dis-
ease. The next months were complicated by dehy-
dration caused by a norovirus infection (age
8 months), and adrenocortical insufficiency (age
10 months) possibly caused by the topical steroids.
At 14 months, little improvement was seen using coal
tar 5% in vaseline-lanette cream and mometasone
ointment 2 to 3 times per week.Sp-1540, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands.
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Fig 1. A, Erythroderma presented at age 7 weeks. B, DITRA with 6 months treatment with
etanercept and acitretin, age 4 years and 3 months.
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generalized pustules including scalp, palms, and
soles. A skin biopsy found parakeratosis and pus-
tules containing neutrophils, supporting a diagnosis
of psoriasis pustulosa. Around this time, the first
publications of DITRA (online Mendelian inheri-
tance in man [OMIM] #614204) appeared3 and
Sanger sequence analysis of the IL36RN gene found
a homozygous mutation, c.80T[C (p.Leu27Pro),
confirming the diagnosis of DITRA at 18 months of
age.
During the course of her disease, multiple systemic
therapies were administered with different outcomes
as illustrated by the PASI (Psoriasis Activation and
Severity Index) scores (mean, 24.0; range, 0.7-57.6)
assessed at different time points and based on clinical
presentation (Fig 2). Cyclosporin (4 mg/kg/d for
2months) induced increase of erythema andpustules.
With anakinra (5 mg/kg/d for 6 days) the pustules
initially disappeared, but within 6 days there was a
flare and persistent erythema. Acitretin was given for
2 years and 8 months at an initial dose scheme
according to Chao et al4 (initially 1 mg/kg/d) and
showed initially a good response with a PASI score of
0.7.4 During the following relapses and remissions,
the acitretin dose varied between 0.4 mg/kg/d and
1 mg/kg/d. Etanercept (12.5 mg/wk) was added to
acitretin with a good response for 6 months, even
reaching a PASI score of 0.0 after the fifth injection of
etanercept (see Fig 2). After 6 months, good improve-
ment is seen with acitretin, 15 mg/d, and etanercept
12.5mg/wk (Fig 1, B). No side effects were noticed by
clinicians or reported by the parents.
DISCUSSION
Deficiency of DITRA is a subgroup of GPP
patients with a specific monogenetic defect3 that is
difficult to treat. Recommendations for first- andsecond-line therapies in GPP patients are made in
cooperation with the Board of the National Psoriasis
Foundation.5 In children, first-line therapies include
acitretin, cyclosporin, methotrexate, and etanercept,
and second line therapies include adalimumab,
infliximab, and ultraviolet B phototherapy.5 There
are no guidelines for the treatment of DITRA, and
most cases presented in literature with therapeutic
outcomes are derived from case reports and case
series, reflecting the extreme rarity of the disorder.
Follow-up periods in these patients, when
mentioned, have been limited. This case illustrates
a patient with juvenile DITRA, showing response to
different systemic therapies and reporting an initially
successful treatment with acitretin and a good
response to acitretin combined with etanercept after
a relapse.
Since the discovery of DITRA in 2011, fewer than
15 juvenile patients with DITRA and corresponding
therapeutic outcomes were documented. The muta-
tion c.80T[C/p.Leu27Pro in our case is identical to
that originally described by Marrakchi et al in 20113
and was only described twice after (Table I). One
described by Rossi-Semerano et al7 was successfully
treated with anakinra (2-4 mg/kg/d for 2 months).7
However, in the case described by Carapito et al,6
treatment with anakinra (5 mg/kg/d for 3 months)
was not successful. In our patient, anakinra in a
similar dose (100 mg/d), had to be stopped after
6 days because of a flare of the disease. Recent
treatment of juvenile DITRA (C11516T[C/
p.Arg10ArgfsX1) with tumor necrosis factor-a
blockers (infliximab) was reported to be successful8
and unsuccessful.9 Similar treatments in patients with
identical mutations result in different outcomes,
illustrating the complexity of the disease and its
treatment. A recent publication showed a possible
correlation between disease severity in DITRA,
Fig 2. PASI scores of our patient during different treatments.
Table I. Therapy outcomes in juvenile patients with c.80T[C/p.Leu27Pro mutation
Study Age Sex Final treatment Duration Response Outcome details Previous treatment(s)
1 Carapito
et al6
8 mo M Anakinra 3 mo None — Canakinumab
2 Rossi-Semerano
et al7
6 wk M Anakinra 2 mo Good Recovery after 8 days, no
flares after 2 months
—
3 Current case 3 y F Acitretin 1
etanercept
6 mo Good — Cyclosporin, topical
steroids, anakinra,
acitretin
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expression.10 Null mutations with complete absence
of IL36RN antagonist (eg, c.80T[C/p.Leu27Pro)
were associated with severe clinical phenotypes
compared with mutations with decreased or un-
changed protein expression.10 As mentioned, little is
known about the treatment in DITRA, and treatment
response is difficult to monitor, because DITRA by its
nature is characterized by remissions and flares.
DITRA patients can lose response to therapy, even
after prolonged use, as is seen in our case withacitretin as monotherapy. Although the therapy with
acitretin and etanercept looks promising within
6 months, diminished therapy effect is still possible.
CONCLUSION
DITRA is a recently described variation of GPP.
Little is known about treatment regimes. Our case of
juvenile DITRA describes a good effect of acitretin in
combination with etanercept for 6 months. Further
research is necessary about optimal treatment for
DITRA in relation to mutation status.
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